|Bid||0.3601 x 1000|
|Ask||0.3850 x 900|
|Day's Range||0.3735 - 0.3850|
|52 Week Range||0.2300 - 2.4600|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT New CRO to facilitate study of the Hemopurifier® in a range of cancers To advance its medical device, the HemoPurifier®, through clinical studies towards potential regulatory approval and commercialization, Aethlon Medical’s (NASDAQ:AEMD) has launched several recent initiatives. Among other steps, the company has: ▪ Embarked on launching
Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.